$EXEL
EXELIXIS, INC. Stock $exel

$exel Overview Financials Valuation SEC Filings Company Website

2017 Q4 Form 10-Q Financial Statement

#000093976717000183 Filed on November 01, 2017

Income Statement

Concept	2017 Q4	2017 Q3	2016 Q3
Revenue	$120.1M	$152.5M	$62.19M
YoY Change	54.77%	145.22%	531.15%
Cost Of Revenue	$4.200M	$4.658M	$2.455M
YoY Change	121.05%	89.74%	72.89%
Gross Profit	$91.52M	$91.76M	$40.29M
YoY Change	82.81%	127.76%	377.67%
Gross Profit Margin	76.22%	60.17%	64.78%
Selling, General & Admin	$46.20M	$38.13M	$32.46M
YoY Change	255.38%	17.45%	81.95%
% of Gross Profit	50.48%	41.55%	80.58%
Research & Development	$32.20M	$28.54M	$20.26M
YoY Change	35.29%	40.91%	-22.36%
% of Gross Profit	35.18%	31.11%	50.28%
Depreciation & Amortization	$400.0K	$300.0K	$300.0K
YoY Change	100.0%	0.0%	-25.0%
% of Gross Profit	0.44%	0.33%	0.74%
Operating Expenses	$78.40M	$71.33M	$54.93M
YoY Change	113.62%	29.86%	20.37%
Operating Profit	$37.43M	$81.18M	$7.264M
YoY Change	-3.73%	1017.57%	-120.3%
Interest Expense	$0.00	$0.00	$7.834M
YoY Change	-100.0%	-100.0%	-21.95%
% of Operating Profit	0.0%	0.0%	107.85%
Other Income/Expense, Net	-$1.200M	$3.408M	-$18.55M
YoY Change		-118.37%	90.02%
Pretax Income	$38.90M	$84.59M	-$11.28M
YoY Change	10.83%	-849.63%	-75.2%
Income Tax	$400.0K	$3.206M	$0.00
% Of Pretax Income	1.03%	3.79%
Net Earnings	$38.49M	$81.38M	-$11.28M
YoY Change	9.58%	-821.22%	-75.22%
Net Earnings / Revenue	32.05%	53.36%	-18.14%
Basic Earnings Per Share	$0.13	$0.28	-$0.04
Diluted Earnings Per Share	$0.12	$0.26	-$0.04
COMMON SHARES
Basic Shares Outstanding	295.9M shares	294.3M shares	256.3M shares
Diluted Shares Outstanding		312.9M shares	256.3M shares

Balance Sheet

Concept	2017 Q4	2017 Q3	2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$387.8M	$367.1M	$319.7M
YoY Change	-7.62%	14.83%	61.63%
Cash & Equivalents	$183.2M	$149.4M	$111.2M
Short-Term Investments	$204.6M	$217.7M	$208.5M
Other Short-Term Assets	$9.300M	$8.000M	$7.100M
YoY Change	72.22%	12.68%	82.05%
Inventory	$6.657M	$5.806M	$3.292M
Prepaid Expenses
Receivables	$77.30M	$90.00M	$91.20M
Other Receivables	$3.892M	$0.00	$0.00
Total Short-Term Assets	$484.9M	$470.9M	$421.3M
YoY Change	3.38%	11.77%	103.2%
LONG-TERM ASSETS
Property, Plant & Equipment	$11.21M	$19.26M	$1.737M
YoY Change	441.43%	1008.58%	19.96%
Goodwill	$63.68M	$63.68M	$63.68M
YoY Change	0.0%	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments	$64.30M	$50.60M	$55.80M
YoY Change	15.65%	-9.32%	-31.62%
Other Assets	$12.09M	$692.0K	$1.774M
YoY Change	881.49%	-60.99%	-72.74%
Total Long-Term Assets	$170.4M	$138.9M	$127.2M
YoY Change	34.47%	9.19%	-18.43%
TOTAL ASSETS
Total Short-Term Assets	$484.9M	$470.9M	$421.3M
Total Long-Term Assets	$170.4M	$138.9M	$127.2M
Total Assets	$655.3M	$609.8M	$548.5M
YoY Change	10.0%	11.17%	51.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.575M	$5.988M	$3.965M
YoY Change	45.85%	51.02%	75.75%
Accrued Expenses	$66.00M	$71.60M	$69.40M
YoY Change	23.6%	3.17%	132.98%
Deferred Revenue	$8.393M
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00	$109.4M
YoY Change	-100.0%	-100.0%	24203.33%
Total Short-Term Liabilities	$115.2M	$109.0M	$201.6M
YoY Change	-57.15%	-45.97%	260.58%
LONG-TERM LIABILITIES
Long-Term Debt	$14.50M	$0.00	$81.49M
YoY Change		-100.0%	-78.41%
Other Long-Term Liabilities	$1.705M	$16.01M	$759.0K
YoY Change	215.16%	2009.62%	-59.65%
Total Long-Term Liabilities	$1.705M	$16.01M	$82.25M
YoY Change	215.16%	-80.53%	-78.32%
TOTAL LIABILITIES
Total Short-Term Liabilities	$115.2M	$109.0M	$201.6M
Total Long-Term Liabilities	$1.705M	$16.01M	$82.25M
Total Liabilities	$370.3M	$371.1M	$516.5M
YoY Change	-26.87%	-28.15%	18.06%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.570B	-$1.868B	-$2.018B
YoY Change	-20.81%	-7.46%	6.6%
Common Stock	$296.0K	$296.0K	$286.0K
YoY Change	2.07%	3.5%	27.11%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$285.0M	$238.7M	$32.00M
YoY Change
Total Liabilities & Shareholders Equity	$655.3M	$609.8M	$548.5M
YoY Change	10.0%	11.17%	51.0%

Cashflow Statement

Concept	2017 Q4	2017 Q3	2016 Q3
OPERATING ACTIVITIES
Net Income	$38.49M	$81.38M	-$11.28M
YoY Change	9.58%	-821.22%	-75.22%
Depreciation, Depletion And Amortization	$400.0K	$300.0K	$300.0K
YoY Change	100.0%	0.0%	-25.0%
Cash From Operating Activities	$53.30M	$37.90M	-$5.800M
YoY Change	-37.37%	-753.45%	-83.09%
INVESTING ACTIVITIES
Capital Expenditures	-$17.70M	-$1.100M	$0.00
YoY Change	2850.0%
Acquisitions
YoY Change
Other Investing Activities	-$700.0K	-$25.40M	-$12.10M
YoY Change	-98.8%	109.92%	-61.59%
Cash From Investing Activities	-$18.30M	-$26.60M	-$12.10M
YoY Change	-68.93%	119.83%	-61.59%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-700.0K	2.900M	-700.0K
YoY Change	-104.43%	-514.29%	-100.47%
NET CHANGE
Cash From Operating Activities	53.30M	37.90M	-5.800M
Cash From Investing Activities	-18.30M	-26.60M	-12.10M
Cash From Financing Activities	-700.0K	2.900M	-700.0K
Net Change In Cash	34.30M	14.20M	-18.60M
YoY Change	-18.33%	-176.34%	-122.25%
FREE CASH FLOW
Cash From Operating Activities	$53.30M	$37.90M	-$5.800M
Capital Expenditures	-$17.70M	-$1.100M	$0.00
Free Cash Flow	$71.00M	$39.00M	-$5.800M
YoY Change	-17.15%	-772.41%	-83.09%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-29
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Period End Date DocumentPeriodEndDate	2017-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0000939767
CY2017Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	295853210	shares
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	0	USD
	dei	Entity Registrant Name EntityRegistrantName	EXELIXIS, INC.
	dei	Trading Symbol TradingSymbol	exel
CY2016Q4	exel	Accrued Clinical Liabilities Current AccruedClinicalLiabilitiesCurrent	14131000	USD
CY2017Q3	exel	Accrued Clinical Liabilities Current AccruedClinicalLiabilitiesCurrent	16181000	USD
CY2016Q4	exel	Accrued Collaboration Liability Current AccruedCollaborationLiabilityCurrent	2046000	USD
CY2017Q3	exel	Accrued Collaboration Liability Current AccruedCollaborationLiabilityCurrent	9137000	USD
	exel	Ci Pdeemedacquiredin Buildto Suit Lease CIPdeemedacquiredinBuildtoSuitLease	0	USD
	exel	Ci Pdeemedacquiredin Buildto Suit Lease CIPdeemedacquiredinBuildtoSuitLease	14530000	USD
CY2016Q4	exel	Cash Cash Equivalentsand Availableforsale Securities CashCashEquivalentsandAvailableforsaleSecurities	479554000	USD
CY2017Q3	exel	Cash Cash Equivalentsand Availableforsale Securities CashCashEquivalentsandAvailableforsaleSecurities	422317000	USD
CY2016Q4	exel	Cash Cash Equivalentsand Availableforsale Securities Amortized Cost Basis CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis	479862000	USD
CY2017Q3	exel	Cash Cash Equivalentsand Availableforsale Securities Amortized Cost Basis CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis	422369000	USD
CY2016Q4	exel	Cash Cash Equivalentsand Availableforsale Securities Gross Unrealized Gain Accumulatedin Investments CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments	14000	USD
CY2017Q3	exel	Cash Cash Equivalentsand Availableforsale Securities Gross Unrealized Gain Accumulatedin Investments CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments	58000	USD
CY2016Q4	exel	Cash Cash Equivalentsand Availableforsale Securities Gross Unrealized Loss Accumulatedin Investments CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments	322000	USD
CY2017Q3	exel	Cash Cash Equivalentsand Availableforsale Securities Gross Unrealized Loss Accumulatedin Investments CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments	110000	USD
	exel	Debt Collateral Number Of Affiliate Banks DebtCollateralNumberOfAffiliateBanks	1	affiliate
	exel	Debt Collateral Number Of Required Investment Accounts DebtCollateralNumberOfRequiredInvestmentAccounts	1	account
	exel	Excess Tax Benefits Sharebased Compensation ExcessTaxBenefitsSharebasedCompensation	1200000	USD
	exel	Increase Decrease Accrued Clinical Liabilities IncreaseDecreaseAccruedClinicalLiabilities	-3184000	USD
	exel	Increase Decrease Accrued Clinical Liabilities IncreaseDecreaseAccruedClinicalLiabilities	2050000	USD
	exel	Increase Decreasein Accrued Collaboration Liability IncreaseDecreaseinAccruedCollaborationLiability	7772000	USD
	exel	Increase Decreasein Accrued Collaboration Liability IncreaseDecreaseinAccruedCollaborationLiability	7091000	USD
	exel	Numberof Productsin Commercial Market NumberofProductsinCommercialMarket	3	product
	exel	Paymentsfor Conversionof Convertible Debt PaymentsforConversionofConvertibleDebt	7134000	USD
	exel	Paymentsfor Conversionof Convertible Debt PaymentsforConversionofConvertibleDebt	0	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6565000	USD
CY2017Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	5988000	USD
CY2016Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	20334000	USD
CY2017Q3	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	19914000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	24882000	USD
CY2017Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	23118000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-416000	USD
CY2017Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-52000	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2072591000	USD
CY2017Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2106132000	USD
CY2016Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3603000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	18346000	USD
CY2017Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5289000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	15029000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	8295000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	182000	USD
CY2016Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	65777000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	65777000	shares
CY2017Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	583000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1108000	shares
CY2016Q4	us-gaap	Assets Assets	595739000	USD
CY2017Q3	us-gaap	Assets Assets	609772000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	469001000	USD
CY2017Q3	us-gaap	Assets Current AssetsCurrent	470921000	USD
CY2016Q4	us-gaap	Assets Fair Value Disclosure Recurring AssetsFairValueDisclosureRecurring	459966000	USD
CY2017Q3	us-gaap	Assets Fair Value Disclosure Recurring AssetsFairValueDisclosureRecurring	413339000	USD
CY2016Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	459966000	USD
CY2017Q3	us-gaap	Available For Sale Securities AvailableForSaleSecurities	413339000	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	14000	USD
CY2017Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	58000	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	322000	USD
CY2017Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	110000	USD
CY2016Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	460274000	USD
CY2017Q3	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	413391000	USD
CY2017Q3	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	134900000	USD
CY2017Q3	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	50568000	USD
CY2017Q3	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	362771000	USD
CY2016Q3	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	0	USD
	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	0	USD
CY2017Q3	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	0	USD
	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	0	USD
CY2017Q3	us-gaap	Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear	84	investment
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	141634000	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	111219000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	151686000	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	149357000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-30415000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-2329000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2017Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	289923798	shares
CY2017Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	295700576	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	289923798	shares
CY2017Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	295700576	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	290000	USD
CY2017Q3	us-gaap	Common Stock Value CommonStockValue	296000	USD
CY2016Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11493000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-105193000	USD
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	81449000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	116102000	USD
CY2016Q3	us-gaap	Contracts Revenue ContractsRevenue	19452000	USD
	us-gaap	Contracts Revenue ContractsRevenue	30414000	USD
CY2017Q3	us-gaap	Contracts Revenue ContractsRevenue	56094000	USD
	us-gaap	Contracts Revenue ContractsRevenue	79108000	USD
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	285308000	USD
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	0	USD
CY2016Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	109122000	USD
CY2017Q3	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	0	USD
CY2016Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	2455000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	4700000	USD
CY2017Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	4658000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	10875000	USD
	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	5200000	USD
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	19665000	USD
CY2017Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	31377000	USD
CY2016Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	237094000	USD
CY2017Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	246092000	USD
	us-gaap	Depreciation Depreciation	800000	USD
	us-gaap	Depreciation Depreciation	800000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	754000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	842000	USD
CY2016Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.44
CY2017Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.28
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.39
CY2016Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.44
CY2017Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.26
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.37
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-200000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-200000	USD
	us-gaap	Gain Loss On Sale Of Other Investments GainLossOnSaleOfOtherInvestments	2494000	USD
	us-gaap	Gain Loss On Sale Of Other Investments GainLossOnSaleOfOtherInvestments	2980000	USD
CY2016Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-13773000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-13773000	USD
CY2017Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-6239000	USD
CY2016Q4	us-gaap	Goodwill Goodwill	63684000	USD
CY2017Q3	us-gaap	Goodwill Goodwill	63684000	USD
CY2016Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-11284000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-105345000	USD
CY2017Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	84588000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	119659000	USD
CY2016Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2017Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3206000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3921000	USD
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	85026000	USD
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	49241000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2436000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-577000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	251512000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	20710000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	12357000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-420000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	676000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2468000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-535000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-689000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	7183000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	12199000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3342000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2530000	USD
	us-gaap	Increase Decrease In Restricted Cash And Investments IncreaseDecreaseInRestrictedCashAndInvestments	-2650000	USD
	us-gaap	Increase Decrease In Restricted Cash And Investments IncreaseDecreaseInRestrictedCashAndInvestments	-10650000	USD
CY2016Q3	us-gaap	Interest Expense InterestExpense	7834000	USD
	us-gaap	Interest Expense InterestExpense	28575000	USD
CY2017Q3	us-gaap	Interest Expense InterestExpense	0	USD
	us-gaap	Interest Expense InterestExpense	8679000	USD
CY2016Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	738000	USD
CY2017Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2856000	USD
CY2016Q4	us-gaap	Inventory Gross InventoryGross	3944000	USD
CY2017Q3	us-gaap	Inventory Gross InventoryGross	6185000	USD
CY2016Q4	us-gaap	Inventory Net InventoryNet	3338000	USD
CY2017Q3	us-gaap	Inventory Net InventoryNet	5806000	USD
CY2016Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	606000	USD
CY2017Q3	us-gaap	Inventory Noncurrent InventoryNoncurrent	379000	USD
CY2016Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	863000	USD
CY2017Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	378000	USD
CY2016Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	2343000	USD
CY2017Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	2951000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	400000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	1200000	USD
CY2016Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1972000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	7424000	USD
CY2017Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1215000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	4986000	USD
CY2017Q3	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	0	USD
CY2016Q4	us-gaap	Liabilities Liabilities	506421000	USD
CY2017Q3	us-gaap	Liabilities Liabilities	371057000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	595739000	USD
CY2017Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	609772000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	268786000	USD
CY2017Q3	us-gaap	Liabilities Current LiabilitiesCurrent	108953000	USD
CY2016Q4	us-gaap	Long Term Debt LongTermDebt	189122000	USD
CY2017Q3	us-gaap	Long Term Debt LongTermDebt	0	USD
CY2016Q4	us-gaap	Long Term Investments LongTermInvestments	55601000	USD
CY2017Q3	us-gaap	Long Term Investments LongTermInvestments	50569000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-72000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-169215000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-155638000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	54628000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	125295000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	112258000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-11284000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-105345000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	81382000	USD
	us-gaap	Net Income Loss NetIncomeLoss	115738000	USD
CY2016Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11284000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-105345000	USD
CY2017Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	81161000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	115370000	USD
CY2016Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-11284000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-105345000	USD
CY2017Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	81175000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	115393000	USD
CY2016Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-18548000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-38338000	USD
CY2017Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3408000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-8820000	USD
CY2016Q4	us-gaap	Notes Payable Current NotesPayableCurrent	80000000	USD
CY2017Q3	us-gaap	Notes Payable Current NotesPayableCurrent	0	USD
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	54930000	USD
	us-gaap	Operating Expenses OperatingExpenses	180880000	USD
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	71330000	USD
	us-gaap	Operating Expenses OperatingExpenses	203926000	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	7264000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-67007000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	81180000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	128479000	USD
CY2016Q3	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1064000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	4787000	USD
CY2017Q3	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1215000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	3761000	USD
CY2016Q3	us-gaap	Operating Leases Rent Expense Sublease Rentals1 OperatingLeasesRentExpenseSubleaseRentals1	908000	USD
	us-gaap	Operating Leases Rent Expense Sublease Rentals1 OperatingLeasesRentExpenseSubleaseRentals1	2637000	USD
CY2017Q3	us-gaap	Operating Leases Rent Expense Sublease Rentals1 OperatingLeasesRentExpenseSubleaseRentals1	0	USD
	us-gaap	Operating Leases Rent Expense Sublease Rentals1 OperatingLeasesRentExpenseSubleaseRentals1	1225000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	16923000	USD
CY2017Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	26356000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1232000	USD
CY2017Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	692000	USD
CY2016Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-209000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	152000	USD
CY2017Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	67000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	364000	USD
CY2016Q3	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	0	USD
CY2017Q3	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	0	USD
CY2016Q3	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	USD
	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	USD
CY2017Q3	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	USD
	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	541000	USD
CY2017Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	16012000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1332000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1530000	USD
CY2016Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3059000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4010000	USD
CY2017Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3408000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	6098000	USD
	us-gaap	Other Than Temporary Impairment Losses Investments Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities	0	USD
	us-gaap	Other Than Temporary Impairment Losses Investments Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities	0	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	5939000	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	-11825000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	2713000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	3012000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	258509000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	248046000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1116000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3449000	USD
	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments	4150000	USD
	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments	11150000	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2017Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5416000	USD
CY2017Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8012000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	100635000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	266335000	USD
	us-gaap	Proceeds From Sale And Maturity Of Other Investments ProceedsFromSaleAndMaturityOfOtherInvestments	2494000	USD
	us-gaap	Proceeds From Sale And Maturity Of Other Investments ProceedsFromSaleAndMaturityOfOtherInvestments	2980000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	2266000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	37294000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	92000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	14000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	9296000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	16532000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	479000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	3053000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	26953000	USD
CY2017Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	42374000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2071000	USD
CY2017Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	19256000	USD
CY2016Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	40444000	USD
CY2017Q3	us-gaap	Receivables Net Current ReceivablesNetCurrent	90005000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	185788000	USD
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20256000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	72166000	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	28543000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	79967000	USD
CY2016Q4	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	4150000	USD
CY2017Q3	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	4650000	USD
CY2016Q3	us-gaap	Restructuring Charges RestructuringCharges	-244000	USD
	us-gaap	Restructuring Charges RestructuringCharges	871000	USD
CY2017Q3	us-gaap	Restructuring Charges RestructuringCharges	0	USD
	us-gaap	Restructuring Charges RestructuringCharges	-32000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1983147000	USD
CY2017Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1867661000	USD
CY2016Q3	us-gaap	Revenues Revenues	62194000	USD
	us-gaap	Revenues Revenues	113873000	USD
CY2017Q3	us-gaap	Revenues Revenues	152510000	USD
	us-gaap	Revenues Revenues	332405000	USD
CY2016Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	42742000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	83459000	USD
CY2017Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	96416000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	253297000	USD
CY2016Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	32463000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	103143000	USD
CY2017Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	38129000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	113116000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	18346000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	15029000	USD
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	15961685	shares
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.41
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	204525	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	821260	shares
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	395212000	USD
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	24999665	shares
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	21333553	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.91
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.72
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.94
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	8.14
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	21.60
CY2017Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	316415000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y7M2D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y0M29D
CY2016Q4	us-gaap	Short Term Investments ShortTermInvestments	268117000	USD
CY2017Q3	us-gaap	Short Term Investments ShortTermInvestments	217741000	USD
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	4282847	shares
CY2016Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	89318000	USD
CY2017Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	238715000	USD
CY2016Q3	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	0	USD
CY2017Q3	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	221000	USD
	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	368000	USD
CY2016Q3	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Diluted UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted	0	USD
	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Diluted UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted	0	USD
CY2017Q3	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Diluted UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted	-14000	USD
	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Diluted UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted	-23000	USD
CY2016Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2017Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	18671000	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	18779000	shares
CY2016Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	256319000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	238024000	shares
CY2017Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	312940000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	311555000	shares
CY2016Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	256319000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	238024000	shares
CY2017Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	294269000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	292776000	shares
	us-gaap	Fiscal Period FiscalPeriod	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">st</sup></font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Fiscal year 2017 will end on December 29, 2017 and fiscal year 2016 ended on December 30, 2016. For convenience, references in this report as of and for the fiscal periods ended September 29, 2017 and September 30, 2016, and as of and for the fiscal years ended December 29, 2017 and December 30, 2016, are indicated as being as of and for the periods ended September 30, 2017 and September 30, 2016, and the years ended December 31, 2017 and December 31, 2016, respectively.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font></div></div>
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Reclassifications</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Certain prior period amounts in the condensed consolidated financial statements have been reclassified to conform to current period presentation. We reclassified </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.8 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in payable to our customers from Other current liabilities to Trade and other receivables in the accompanying December 31, 2016 Condensed Consolidated Balance Sheet. We have also reclassified the related balances between line items in Changes in assets and liabilities in the accompanying Condensed Consolidated Statement of Cash Flows for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">nine months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September 30, 2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to conform the presentation of those line items to the corresponding presentation of assets and liabilities in our accompanying Condensed Consolidated Balance Sheets.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The preparation of our condensed consolidated financial statements conforms to accounting principles generally accepted in the U.S. which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to, those related to revenue recognition, including deductions from revenues (such as rebates, chargebacks, sales returns and sales allowances), the period of performance, identification of deliverables and evaluation of milestones with respect to our collaborations, the amounts of revenues and expenses under our profit and loss sharing agreement, recoverability of inventory, certain accrued liabilities including accrued clinical trial liability, and stock-based compensation. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0000939767-17-000183-index-headers.html	Edgar Link	pending
0000939767-17-000183-index.html	Edgar Link	pending
0000939767-17-000183.txt	Edgar Link	pending
0000939767-17-000183-xbrl.zip	Edgar Link	pending
exel-20170929.xml	Edgar Link	completed
exel-20170929.xsd	Edgar Link	pending
exel-20170929_cal.xml	Edgar Link	unprocessable
exel-20170929_def.xml	Edgar Link	unprocessable
exel-20170929_lab.xml	Edgar Link	unprocessable
exel-20170929_pre.xml	Edgar Link	unprocessable
exel2017093010-q.htm	Edgar Link	pending
exel20170930exhibit102.htm	Edgar Link	pending
exel20170930exhibit103.htm	Edgar Link	pending
exel20170930exhibit104.htm	Edgar Link	pending
exel20170930exhibit121.htm	Edgar Link	pending
exel20170930exhibit311.htm	Edgar Link	pending
exel20170930exhibit312.htm	Edgar Link	pending
exel20170930exhibit321.htm	Edgar Link	pending
exellogo201709.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EXEL
EXELIXIS, INC. Stock $exel

2017 Q4 Form 10-Q Financial Statement

#000093976717000183 Filed on November 01, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EXEL EXELIXIS, INC. Stock $exel

2017 Q4 Form 10-Q Financial Statement

#000093976717000183 Filed on November 01, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EXEL
EXELIXIS, INC. Stock $exel